Overview

Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower Limbs

Status:
Completed

Trial end date:
2012-12-01

Target enrollment:

Participant gender:

Summary

To assess the safety and pharmacokinetics of DU-176b administered to patients with severe renal impairment undergoing orthopedic surgery of the lower limbs, compared with DU-176b administered to patients with mild renal impairment (MiRI) undergoing orthopedic surgery of the lower limbs. For reference, the safety of DU-176b in patients with SRI undergoing orthopedic surgery of the lower limbs will be compared with that of fondaparinux.

Phase:

Phase 3

Details

Lead Sponsor:

Daiichi Sankyo Co., Ltd.

Treatments:

Edoxaban
Fondaparinux
PENTA